chrisvoncsefalvay/vaers-outcomes huggingface dataset:
stroke-like symptoms: numbness in left fingers, unsteadiness on feet, speech abnormalities, confused thinking/diagnosed with a right MCA stroke; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 54-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 27Oct2022 as dose 5 (booster), single (Batch/Lot number: unknown) at the age of 54 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "covid prior vaccination yes" (unspecified if ongoing); "Known allergies: yes" (unspecified if ongoing). No other medical history. Concomitant medication(s) included: OLMESARTAN; PROBIOTICS; FIBER. No other vaccine in four weeks. Medications in two weeks included Olmesartan, multivitamin/mineral, probiotic, fiber. Vaccination history included: BNT162b2 (Dose Number: 4, Batch/Lot No: FJ4991, Location of injection: Arm Left), administration date: 28Jul2022, when the patient was 54-year-old, for Covid-19 immunization; BNT162b2 (Dose Number: 3, Batch/Lot No: FD7218, Location of injection: Arm Left), administration date: 13Dec2021, when the patient was 53-year-old, for Covid-19 immunization; BNT162b2 (Dose Number: 2, Batch/Lot No: ER8728, Location of injection: Arm Left), administration date: 07Apr2021, when the patient was 53-year-old, for Covid-19 immunization; BNT162b2 (Dose Number: 1, Batch/Lot No: EN6207, Location of injection: Arm Left), administration date: 17Mar2021, when the patient was 53-year-old, for Covid-19 immunization. The following information was reported: CEREBROVASCULAR ACCIDENT (hospitalization, medically significant) with onset 22Nov2022 at 08:00, outcome "recovering", described as "stroke-like symptoms: numbness in left fingers, unsteadiness on feet, speech abnormalities, confused thinking/diagnosed with a right MCA stroke". The patient was hospitalized for cerebrovascular accident (hospitalization duration: 3 day(s)). The event "stroke-like symptoms: numbness in left fingers, unsteadiness on feet, speech abnormalities, confused thinking/diagnosed with a right mca stroke" required emergency room visit. Therapeutic measures were taken as a result of cerebrovascular accident included medical testing and medications. Clinical course: On 22Nov2022, patient began having stroke-like symptoms: numbness in left fingers, unsteadiness on feet, speech abnormalities, confused thinking. Patient reported to the emergency room and was diagnosed with a right MCA stroke.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
pt w/ near syncope at time of administration of vaccine pt roused almost immediately, was diaphoretic, tremulous and felt weak
Around 11/17/2022 I had a high temperature (101.8 degrees), nasal congestion, sore throat, it lasted 5 days, I contacted my doctor and prescribed Paxlovid, I took it for 5 days and symptoms improved, and I have been fine since then, I tested Positive on 11/17 at home COVID-19 and on the 11/18 I had a PCR COVID-19 test and test ed positive. on 11/23 I had another home test, and it was Negative.
From initial information received on 10/20/04 from the patient's mother regarding an adverse event occurring in the USA, it was reported that a 21 year old male patient that had previously been diagnosed with psychosis and also has a past medical history of severe head injuries with encephalopathy, leg injuries, and Lyme disease received a TD ADS ADULT vaccination, lot number not reported, administered in July 2004 for a Lyme bite. That evening the patient developed shaking of the head and complained of feeling his throat was closing and feeling foggy. Since the vaccination the patient has developed incontinence and has had a loss of appetite. Reportedly these symptoms persist and the patient was reported as not recovered. (OMIC).
BLOOD CLOT TO LEFT LEG; DAMAGED HEART MUSCLE; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age, sex, race and ethnicity. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin and batch number were not reported and expiry: Unknown) dose was not reported, 1 total administered on an unspecified date for covid-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced blood clot to left leg that damaged heart muscle. It was reported that the patient seen cardiologist where the patient was concluded after many tests (Lab test) and treatments, that the blood clot to left leg that damaged heart muscle. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the blood clot to left leg and damaged heart muscle was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20221247202-blood clot to left leg. Insufficient information is available to make a causality assessment. Therefore, this event is considered unclassifiable.
Approximately 2 days after the Patient receiving the PREVNAR vaccine to his right arm's deltoid muscle, he started to have severe pain to his entire right arm and numbness to 2 of his smallest fingers of his right hand. Patient stated that it reached 10 out of 10 of pain to his right arm but he didn't seek for any doctor or nurse until I called his primary doctor on 8/22/17. He stated that his pain has not been as bad on 8/22/17 but still quiet painful and that's why I contacted his doctor. The next day (8/23/17), the primary doctor sent a script of Gabapentin 100 mg TID. The patient is doing much better in the evening of 8/24/17 and his pain seems to be in a much better control.
On 12/6/99, the pt developed breakthrough chickenpox with 20 lesions on the first day. On the same day, the pt was seen by a physician. At the time of reporting, the pt's breakthrough chickenpox persisted.
This case was reported by a pharmacist via call center representative and described the occurrence of pimples in a 69-year-old female patient who received SHINGRIX (batch number Z9RR4, expiry date 15th November 2020) for prophylaxis. Previously administered products included SHINGRIX with an associated reaction of injection site rash (1st dose administered on 2nd April 2018 (refer case US2018111999)) and MMR vaccine. On 22nd June 2018, the patient received the 2nd dose of SHINGRIX (intramuscular) .5 ml. On 22nd June 2018, 10 min after receiving SHINGRIX, the patient experienced pimples and injection site reaction. On an unknown date, the outcome of the pimples and injection site reaction were unknown. The reporter considered the pimples and injection site reaction to be probably related to SHINGRIX. Additional information was reported as follows: The patient came to the pharmacy to receive her 2nd dose of SHINGRIX vaccine, at that time the pharmacist monitored that after her injection the patient had a small pimple appeared at the injection site.
Approximately 10 days after the first injection, a 1 cm round, multi-colored raised lesion/growth began to grow on my left temple (head). In time, it became sensitive and eventually bled.  Treatment was on 9/8/2021 and the lesion/growth was cut off and sent for analysis.  Lesion/growth was found to be benign and there has been no signs of the lesion/growth returning
side effects after the first shot; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (side effects after the first shot) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (side effects after the first shot). At the time of the report, VACCINATION COMPLICATION (side effects after the first shot) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment medications were reported.
Fever - 101, chills and dizziness. Rotating Tylenol and Motrin every 6 hours.  Was seen by primary care physician.
23JUN94 pt exp sneezing, itchy nose-throat felt tight-OK swallowing & breathing; 215PM p100; eyelids puffy;
hives/itchiness started to occur 11Feb2021 mainly at night.; hives/itchiness started to occur 11Feb2021 mainly at night.; This is a spontaneous report from a contactable consumer (patient). This 62-year-old non-pregnant female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot number: EL3248, expiry date not reported) via unspecified route of administration on 28Jan2021 18:45 (at age of 62-years) as single dose for covid-19 Immunisation. Patient medical history include allergic to cobalt dichloride, quaternium 15, nickel, potassium dichromate, neomycin,p-tert-Butylphenol formaldehyde resin, epoxy resin, carba mix, thimerosal, CI+ Me-Isothiazolinone. Patient had allergen patch test in Jun2011. Patient concomitant medications include Calcium, colecalciferol (D3), ascorbic acid(Vit C), Multi Vit,chondroitin sulfate sodium, glucosamine hydrochloride (Glucosamine Chondr) for unspecified indication from unspecified date. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with covid-19. Post vaccination, the patient was not tested for covid. On 11Feb2021(after 14days of vaccination) patient experienced Hives/itchiness started to occur mainly at night. Events resulted in clinic visit. Patient had video visit for physician on 15Feb2021 for events. Patient received treatment Zyrtec 1x per day; Benadryl if needed at night. Even though 2 weeks after 1st vaccine, physician prescribed .The clinical outcome of events was unknown.  Follow-up attempts are completed. No further information is expected.
This spontaneous report received from a patient (pharmacist) via other company (Pfizer) concerned a 34 year old female of an unspecified race and ethnic origin. The patient's weight was 58.97 kilograms, and height was 155 centimeters. The patient's concurrent conditions included: asthma. The patient was a pharmacy technician. On an unspecified date, the patient received first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin not reported, batch number: unknown, expiry: unknown) dose was not reported, 1 in total administered for prophylactic vaccination. The batch number was not reported and has been requested.  It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1). On JUN-2022, the patient received first booster shot (second dose) of non-company suspect vaccine tozinameran (Pfizer) (dose number in series 2) (form of admin and route of admin were not reported, batch number: FM7553 expiry: UNKNOWN) dose was not reported, administered to left arm for prophylactic vaccination. No concomitant medications were reported.  On JUN-2022, the patient experienced sore arm and hand pain for 2 to 3 days (dose number in series 2). On 15-JUN-2022, the patient felt her right side of the face that somebody punched, eye hurt a lot and her face was numb on the right side only (dose number in series 2). The patient had not received any treatment. The action taken with covid-19 vaccine ad26.cov2.s, and tozinameran was not applicable. The patient recovered from sore arm/hand pain on JUN-2022, and the outcome of eye hurting a lot, face is numb on the right side and felt like right side of face that somebody punched was not reported. This report was non-serious.
It feels a little tender when she touches it; swollen lymph nodes; This is a follow up spontaneous report from a Contactable consumer. A 73 year old female patient received the first dose of the bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot number and expiration date was not reported), via an unspecified route of administration in the left arm on 29Jan2021 10:00AM and 10:15AM at single dose for COVID-19 immunization. Medical history included swollen lymph nodes and bone density abnormal. Concomitant medications included Strontium and Algae Cal Plus. On 01Feb2021 patient developed swollen lymph nodes. Upon follow up 03Feb2021, It feels a little tender when she touches it. The outcome of events was unknown.  Follow up (03Feb2021): This is a follow up spontaneous report from a Contactable consumer included: medical history, concomitant medications, and event information.  Information on the Lot/Batch number has been requested
booster of vaccine; injection site swelling; muscle aches in arm pit area and across chest; feverish symptoms; This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP) from a sales representative. The reporter is the patient.  A 49 year-old male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Covid-19 vaccine (Dose: 1, Manufacturer Unknown), for COVID-19 immunisation; Covid-19 vaccine (Dose: 2, Manufacturer Unknown), for COVID-19 immunisation. The following information was reported: IMMUNISATION (non-serious), outcome "unknown", described as "booster of vaccine"; VACCINATION SITE SWELLING (non-serious), outcome "unknown", described as "injection site swelling"; MYALGIA (non-serious), outcome "unknown", described as "muscle aches in arm pit area and across chest"; PYREXIA (non-serious), outcome "unknown", described as "feverish symptoms". Additional information: Patient was healthy. Symptoms include injection site swelling, muscle aches in arm pit area and across chest, and feverish symptoms 12 hours after taking 3rd booster of vaccine. Event took place after use of product. No underlying conditions.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This is a spontaneous report from a Pfizer- sponsored program. A 34-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot Number: EN0164; Expiration Date: Aug 2021), via an unspecified route of administration, administered in Arm Left on 14May2021 14:00 as 1st dose, single dose for COVID-19 immunization. Medical history included COVID-19 from Nov2020 to an unknown date. The patient's concomitant medications were not reported. No other vaccinations within four weeks prior to the first administration date of the suspect vaccine was reported. The patient experienced she developed a rash on her neck on 15May2021, fever on 15May2021 21:00, there were bruises on her ankles on (she visited physician office), chills on May2021, hot sweat like on 15May2021 07:00. She wanted to know if this has happened to other people after receiving, the vaccine she also wants to know if she should still receive the 2nd dose of the Pfizer-BioNTech COVID-19 Vaccine after having a side effect with the 1st dose. Patient stated she saw online about the rash; she notices she had a very faint rash on her neck and didn't really bother her; that went away pretty quickly. The chills and the fever, she knew that this was a side effect, and it didn't last long at all. The patient underwent lab tests and procedures which included blood test normal on 17May2021 for blood work. The outcome of event she developed a rash on her neck recovered on 19May2021 and fever on 16May2021. The outcome of contusion was not recovered, the outcome of chills and hot sweat like was unknown. Follow-up attempts are needed. Further information is expected. .
Fever up to 102.7 degrees F with RUE warmness/erythema: ID consulted. Imaging, lab, cultures, antibiotics ordered.
Covid symptoms and two positive tests. Had covid for 12 days. Started with sore throat, but did not test positive for two days after. Struggled to get enough oxygen, coughing, sneezing, headache, fatigue, diarrhea, body aches, sore throat for 10 days.
10/30/2015 6 AM shortness of breath. 12:30 PM acute tachycardia. 1:42 pulse with hot flushing, clamminess and weakness. Also site reaction of redness, pain and itching and swelling as well as bruising, Blood pressure of 145/102. 10/30/15  11/1/15 continuing erratic pulse continued with pulse in 90's until morning of 11/1/15.
Site: Bruising at Injection Site-Mild, Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Severe, Site: Redness at Injection Site-Severe, Site: Swelling at Injection Site-Medium, Systemic: Allergic: Rash Generalized, Systemic: Fever, Systemic: Joint Pain
This spontaneous report has been received from a medical assistant referring to a patient of unknown age and gender. Information about concomitant medication, pertinent medical history and drug reactions/allergies was not provided. On 20-NOV-2018, the patient was vaccinated with improperly stored ROTATEQ (lot # R015432, expiration date 15-APR-2020) for prophylaxis (strength, dose detail, anatomical location and route of administration were not reported). No adverse effect was reported. The vaccine was exposed to temperature excursion between 0 degree Celsius (C) and 1 degree C for a time frame of 19 minutes and between 9 degree C and 25 degree C for 1 hour without previous temperature excursion. Data logger was involved. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1901USA001125.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 37-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 08Sep2022 as dose 5 (booster), single (Lot number: GH9694) at the age of 37 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Onions" (unspecified if ongoing); "sun allergy" (unspecified if ongoing); "Cancer survivor. Finished chemo", stop date: Apr2022, notes: Cancer survivor. Finished chemo in Apr2022.; "Cancer survivor. Finished chemo" (unspecified if ongoing), notes: Cancer survivor. Finished chemo in Apr2022. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 03Mar2023, outcome "not recovered" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (03Mar2023) Positive, notes: Tested positive on 03Mar and started Paxlovid in the evening; (08Mar2023) Negative, notes: Finished the last set of pills on morning of 08Mar and tested negative; (10Mar2023) Negative, notes: Tested negative again on 10Mar; (12Mar2023) Positive, notes: Tested positive again on 12Mar. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Paxlovid rebound. Tested positive on 03Mar and started Paxlovid in the evening. Finished the last set of pills on morning of Mar8 and tested negative. Tested negative again on 10Mar with no symptoms. On 12Mar, started coughing and sneezing. Tested positive again on 12Mar. Symptoms worsened on 13Mar and 14Mar.
pt recv vax 5NOV97 & same day felt warm;got up to leave & fainted;
Fever, wheeze, blood shot eyes, fatigue was (+) (positive) for Influenza Type B.
Patient received vaccine at 1513, walked to observation area, upon sitting, fell to the ground. Within 1min of being approached was able to verbally answer questions. Patient complained of pain on right side of face and tongue. Vital signs were initiated, WNL, patient was provided ice packs, water and crackers; moved to a cooling center after she stated she was feeling better. EMS arrived on site at 1525, took over. Patient was encouraged to go to hospital, patient declined,  was educated to follow up with primary healthcare provider. Patient left at 1535 with father, who was driving.
FOLLOW-up information provided outcome. Information regarding PREVNAR was received from a healthcare professional regarding a 4-month-old female patient who experienced rash with urticaria like qualities.  At 4 months of age, the patient received a dose on 14-Jan-2008.  The patient also received a dose of COMVAX (Merck Sharp & Dome), a dose of DTaP (manufacturer unknown), a dose of IPOL and a dose of ROTATEQ (Merck & Co Inc) on 14-Jan-2008.  Relevant medical history was not provided.  Product was administered on 14-Jan-2008.  Additional suspect medication included COMVAX (Merck Sharp & Dome), DTaP (manufacturer unknown), ROTATEQ (Merck & Co Inc) and IPOL.  Concomitant medications were not reported.  The patient experienced rash with urticaria like qualities on 15-Jan-2008.  The rash was primarily around the facial area and arms.  Outcome was unknown.  No additional information was available at the time of this report. The patient experienced rash with urticaria like qualities on 15-Jan-2008. The rash was primarily around the facial area and arms. The patient recovered. No additional information was available at the time of this report.
I got symptoms of tiredness when I got off the airplane. Then when I got home I had aches and pains with flu like symptoms. Then had chills and runny nose. I took Advil PM and went to bed. I had somewhat of a cough and runny nose so I went and got a home COVID-19 test that was positive. I did eventually lose my taste and smell. Some of my symptoms lasted for months especially my lose of taste and smell and energy. I still have brain fog and I take Vitamin B12 that seems to help.
Aprox 40 min after vaccine, pt was walking dog and started feeling funny i.e light headed, swelling tongue/throat, dizzy and felt like she was having an anaphylactic reaction. Her husband transported her to Care Clinic where she fainted in the waiting area and was unconscious for about 1 min. BP 60/30 - O2% 81 on room air. Clinic admin IV fluid, Benadryl PO and called ambulance. Admin IM Epi, zofran. decadron, and ativan. Pt arrived at hospital and was monitored aprox 5-6 hours until release. They were unsure if this was anaphylaxis related to flu vaccine (which she gets every year w/o incidence) or another outside factor. Pt is well versed in anaphylaxis and states she has never had before and has not changed any household or beauty products that might cause any type of reaction.